Table 3 :

Clinical Trials of Remdesivir for Treatment of COVID-19

Study ID	Study Design	Location	Sponsor	Study size (randomization)	Primary endpoint/outcome
Completed Status
NCT04257656 (terminated)	Double-blind, placebo-controlled (Severe)	Beijing, China	Capital Medical University, China	N=453 (2:1) 10d RDV:Placebo	Time to clinical improvement by Day 28
NCT04252664 (suspended)	Double-blind, placebo-controlled (Mild/Moderate)	Wuhan, China	Capital Medical University, China	N=308 (1:1) 10d RDV:Placebo	Time to clinical recovery by Day 28
NCT04292899	Open-label (Severe)	Global	Gilead	Part A N=400 (1:1) 10d RDV:5d RDV	Endpoint: Clinical status at Day 14 on 7-point ordinal scale
NCT04292730	Open-label (Moderate)	Global	Gilead	Part A N=600 (1:1:1) 10d RDV:5d RDV:SoC	Endpoint: Clinical status at Day 11 on 7-point ordinal scale
NCT04280705	Adaptive, double-blind, placebo-controlled	Global	NIAID	N=572 (1:1) 10d RDV:Placebo	Outcome: Time to recovery [Time Frame: Day 1 through Day 29]
Recruiting Status
NCT04315948	Adaptive, open-label	Europe	WHO/Institut National de la Santé Et de la Recherche Médicale, France	N=3100 (1:1:1:1:1) 10d RDV:LPV/r: LPV/r+IFN: Hydroxychloroquine:SoC	Outcome: Percentage of subjects reporting each severity rating on a 7-point ordinal scale [Time Frame: Day 15]
Solidarity Master Protocol	Adaptive, double-blind, placebo-controlled	Global	WHO	(1:1:1:1:1) 10d RDV:LPV/r: LPV/r+IFN: Hydroxychloroquine:SoC	Outcome: Clinical status assessed by a 7-point ordinal scale on Day 15

Refer to https://clinicaltrials.gov/ and WHO for complete trial information